Influenza B Virus Hemagglutinin vs Nivolumab
Influenza B Virus Hemagglutinin vs Nivolumab: Overview
This comparison examines the pharmacological differences between Influenza B Virus Hemagglutinin and Nivolumab.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Pharmacokinetics
Half-life: Nivolumab β 27 days.
Chemical Properties
Type: Influenza B Virus Hemagglutinin β Vaccine component; Nivolumab β Antibody.